The goal of the study was to investigate if quantitative ADC can be used as an early imaging biomarker for predicting the treatment response to chemoradiation in esophageal cancer. Using pathological findings as the gold standard, our study demonstrated that the change in quantitative ADC from baseline (before treatment) to interim (two weeks after the initiation of treatment) was highly predictive of whether patients had residual tumors at the end of their treatment.
This abstract and the presentation materials are available to members only; a login is required.